Zealand Pharma Valuation
| ZLDPF Stock | USD 101.61 0.64 0.63% |
At this time, the company appears to be overvalued. Zealand Pharma AS maintains a prevalent Real Value of $90.1 per share. The last-minute price of the company is $101.61. Our model calculates the value of Zealand Pharma AS from examining the company fundamentals such as Shares Outstanding of 51.28 M, operating margin of (3.82) %, and Return On Asset of -0.48 as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Zealand Pharma's price fluctuation is very steady at this time. Calculation of the real value of Zealand Pharma AS is based on 3 months time horizon. Increasing Zealand Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Zealand pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Zealand Pharma AS. Since Zealand Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zealand Pink Sheet. However, Zealand Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 101.61 | Real 90.1 | Hype 101.61 | Naive 103.21 |
The real value of Zealand Pink Sheet, also known as its intrinsic value, is the underlying worth of Zealand Pharma AS Company, which is reflected in its stock price. It is based on Zealand Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Zealand Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Zealand Pharma AS helps investors to forecast how Zealand pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zealand Pharma more accurately as focusing exclusively on Zealand Pharma's fundamentals will not take into account other important factors: Zealand Pharma Total Value Analysis
Zealand Pharma AS is at this time projected to have takeover price of 1.45 B with market capitalization of 1.57 B, debt of 647.91 M, and cash on hands of 864.44 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Zealand Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.45 B | 1.57 B | 647.91 M | 864.44 M |
Zealand Pharma Investor Information
About 56.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 3.26. Zealand Pharma AS had not issued any dividends in recent years. Based on the key measurements obtained from Zealand Pharma's financial statements, Zealand Pharma AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Zealand Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zealand Pharma has an asset utilization ratio of 14.15 percent. This implies that the Company is making $0.14 for each dollar of assets. An increasing asset utilization means that Zealand Pharma AS is more efficient with each dollar of assets it utilizes for everyday operations.Zealand Pharma Ownership Allocation
Zealand Pharma AS retains a total of 51.28 Million outstanding shares. Over half of Zealand Pharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Zealand Pharma Profitability Analysis
The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Zealand Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Zealand Pharma and how it compares across the competition.
About Zealand Pharma Valuation
The pink sheet valuation mechanism determines Zealand Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Zealand Pharma. We calculate exposure to Zealand Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zealand Pharma's related companies.Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 237 people.
8 Steps to conduct Zealand Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Zealand Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Zealand Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Zealand Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Zealand Pharma's revenue streams: Identify Zealand Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Zealand Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Zealand Pharma's growth potential: Evaluate Zealand Pharma's management, business model, and growth potential.
- Determine Zealand Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Zealand Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Zealand Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Zealand Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 43.2 M | |
| Retained Earnings | -3.3 B |
Complementary Tools for Zealand Pink Sheet analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stocks Directory Find actively traded stocks across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |